文献速递心律失常血脂与心血管预防

老年患者中的亚临床心房颤动

Subclinical Atrial Fibrillation in Older Patients.
PubMed 文献 · Circulation · 2017-08-04

在无房颤史的65岁以上心内科或神经内科门诊患者中,植入皮下心电监测仪发现亚临床房颤(SCAF)检出率高达34.4%/年。SCAF的基线预测因素包括年龄、左房内径和血压,但既往卒中史并非预测因素。

要点

  • 无房颤史的老年门诊患者中SCAF常见,年检出率34.4%。
  • 年龄增长、左房扩大是SCAF的预测因素。
  • 既往卒中史与SCAF检出率无显著关联。

核心结论

  • 在无房颤史的老年心内科和神经内科门诊患者中,连续心电监测可频繁检出SCAF。
  • SCAF的临床意义尚不明确。

研究设计与样本

  • 植入皮下心电监测仪(St. Jude CONFIRM-AF),监测持续≥5分钟的SCAF,随访16.3±3.8个月。

主要发现

  • 90例患者检出SCAF≥5分钟,检出率34.4%/年(95%CI 27.7-42.3)。
  • SCAF的基线预测因素包括年龄(每十年HR 1.55,95%CI 1.11-2.15)、左房内径(每厘米HR 1.43,95%CI 1.09-1.86)和血压(每10 mmHg HR 0.87,95%CI 0.78-0.98)。
  • 既往卒中、TIA或系统性栓塞史并非SCAF的预测因素(有卒中史年检出率39.4% vs 无卒中史30.3%,P=0.32)。
  • 左房容积高于中位数73.5 mL的患者SCAF累积检出率更高(51.9%/年)。

关键数值与推荐

  • SCAF定义为持续≥5分钟的无症状房颤发作。
  • 入组条件包括CHA2DS2-VASc评分≥2、睡眠呼吸暂停或BMI>30 kg/m²,且左房扩大(≥4.4 cm或容积≥58 mL)或NT-proBNP≥290 pg/mL。

临床怎么用

  • 对于无房颤史的老年门诊患者,尤其是左房扩大或NT-proBNP升高者,应考虑连续心电监测以筛查SCAF。
  • SCAF检出后的抗凝治疗决策需个体化,因其临床意义尚未明确。

局限性

  • SCAF的临床意义(如卒中风险)未在本研究中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term continuous electrocardiographic monitoring shows a substantial prevalence of asymptomatic, subclinical atrial fibrillation (SCAF) in patients with pacemakers and patients with cryptogenic stroke. Whether SCAF is also common in other patients without these conditions is unknown. METHODS: We implanted subcutaneous electrocardiographic monitors (St. Jude CONFIRM-AF) in patients ≥65 years of age attending cardiovascular or neurology outpatient clinics if they had no history of atrial fibrillation but had any of the following: CHA2DS2-VASc score of ≥2, sleep apnea, or body mass index >30 kg/m2. Eligibility also required either left atrial enlargement (≥4.4 cm or volume ≥58 mL) or increased (≥290 pg/mL) serum NT-proBNP (N-terminal pro-B-type natriuretic peptide). Patients were monitored for SCAF lasting ≥5 minutes. RESULTS: Two hundred fifty-six patients were followed up for 16.3±3.8 months. Baseline age was 74±6 years; mean CHA2DS2-VASc score was 4.1±1.4; left atrial diameter averaged 4.7±0.8 cm; and 48% had a prior stroke, transient ischemic attack, or systemic embolism. SCAF ≥5 minutes was detected in 90 patients (detection rate, 34.4%/y; 95% confidence interval [CI], 27.7-42.3). Baseline predictors of SCAF were increased age (hazard ratio [HR] per decade, 1.55; 95% CI, 1.11-2.15), left atrial dimension (HR per centimeter diameter, 1.43; 95% CI, 1.09-1.86), and blood pressure (HR per 10 mm Hg, 0.87; 95% CI, 0.78-0.98), but not prior stroke. The rate of occurrence of SCAF in those with a history of stroke, systemic embolism, or transient ischemic attack was 39.4%/y versus 30.3%/y without (P=0.32). The cumulative SCAF detection rate was higher (51.9%/y) in those with left atrial volume above the median value of 73.5 mL. CONCLUSIONS: SCAF is frequently detected by continuous electrocardiographic monitoring in older patients without a history of atrial fibrillation who are attending outpatient cardiology and neurology clinics. Its clinical significance is unclear. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01694394.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Healey JS, Alings M, Ha A, et al. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017. PMID: 28778946. doi:10.1161/CIRCULATIONAHA.117.028845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。